Belgian Cancer Registry

CANCER FACT SHEET 2024
TESTICULAR CANCER
ICD-10 C62

CONCEPTS AND ABBREVIATIONS

Absolute numbers (N): The number of newly registered cancer diagnoses observed for a given period of time. All figures and numbers in this cancer fact sheet are based on diagnoses of Belgian residents.

Average Annual Percentage Change (AAPC): The average relative chance in incidence risk from one year to the next. For example an AAPC of 1.05 (a 5% increase) applied to a cancer risk of 200/100,000 results in a risk of 210/100,000 one year later (=200*1.05) and 255/100,000 over 5 years (=200*$(1.05)^5$).

Crude Rate (CR): The crude rate is obtained by dividing the absolute number of diagnoses (N) by the corresponding population size at risk (N/100,000).

ESR2013: Incidence rates standardised to the 2013 revised European Standard Population (ESP): Standardisation is necessary to accommodate for differences in population size and age distribution (over time or among regions). An important factor in interpreting trends in cancer incidence is population ageing, as cancer is an age-dependent disease. For a higher proportion of elderly people in the population, a higher total number of cancer diagnoses can be expected for the same cancer risk. When only absolute numbers (N) or Crude Rate (CR) results are used, a misleading picture of the actual changes in the risk of a cancer diagnosis could be obtained. Therefore, direct standardisation is necessary to evaluate the evolution of the risk of cancer diagnosis over time or among regions.

Net survival: Often also called the relative survival, is an estimate of the survival probability when other causes of death beside the cancer type(s) under study are excluded. As examples of other causes of death, patients with the cancer type(s) under study could also die because of an accident or unrelated cardiac conditions, etc. Net survival may exceed 100%, this occurs when the observed survival probability for patients with the cancer type(s) under study is higher than the one for the matched general population (no excess mortality due to cancer).

The net survival estimation was based on the regional lifetables 2024, obtained from Statbel.

Stage: Cancers are reported with a stage, labelled with a Roman numeral with III being the most advanced stage. Stage is based on the T-category (extent of the tumour), the N-category (absence or presence and extent of the regional lymph node metastasis) and the M-category (absence or presence of distant metastasis). Stage is reported as clinical and pathological stage and as a combination of both clinical and pathological stage with priority given to the pathological stage. Clinical information about distant metastases (cM) will always be taken into account, and in case of neo-adjuvant therapy, priority is given to the clinical stage. If stage is unknown, not applicable or not submitted to the Belgian Cancer Registry, the stage is reported as 'unregistered stage'. Stage is reported according to the TNM 8th edition: J.D. Brierley, M.K. Gospodarowicz, Ch. Wittekind. TNM Classification of Malignant Tumours, 8th edition: UICC, 2017.

95% CI: 95% Confidence Intervals are indicated with a shaded band or whiskers in the figures. The 95% CI is a range of values that has 95% chance to contain the true mean value.

Belgian Cancer Registry

TABLE OF CONTENTS

1. CANCER INCIDENCE 5

1.1. Testicular cancer incidence: by region 5

1.1.1. Testicular cancer incidence by region: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2024 5

1.2. Testicular cancer incidence: by tumour stage 6

1.2.2. Testicular cancer incidence by clinical stage (cStage) and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 6

1.2.3. Testicular cancer incidence by pathological stage (pStage) and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 6

1.2.4. Testicular cancer incidence by stage and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 7

1.3. Testicular cancer incidence: by tumour type 8

1.3.5. Testicular cancer incidence by tumour type and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 8

1.3.6. Testicular cancer incidence by tumour type, stage and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 8

2. CANCER INCIDENCE TRENDS 9

2.1. Testicular cancer incidence trends: by region 9

2.1.1. Testicular cancer incidence trends by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 9

2.2. Testicular cancer incidence trends: by tumour stage 11

2.2.2. Testicular cancer incidence trends by stage: number of new diagnoses, crude and age-standardised incidence rates, 2020-2024, including average annual percentage change from 2004 onwards 11

2.3. Testicular cancer incidence trends: by age group 12

2.3.3. Testicular cancer incidence trends by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 12

3. CANCER PREVALENCE 13

3.1. Testicular cancer prevalence: by region 13

3.1.1. Testicular cancer prevalence by region: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2024 13

4. CANCER SURVIVAL 14

4.1. Testicular cancer survival: by region 14

4.1.1. Testicular cancer survival by region and age group: number at risk and net survival probabilities, 2015-2024 14

4.2. Testicular cancer survival: by tumour stage 15

4.2.2. Testicular cancer survival by clinical stage (cStage): number at risk and net survival probabilities, 2015-2024 15

4.2.3. Testicular cancer survival by pathological stage (pStage): number at risk and net survival probabilities, 2015-2024 15

4.2.4. Testicular cancer survival by stage: number at risk and net survival probabilities, 2015-2024 16

4.3. Testicular cancer survival: by tumour type 16

4.3.5. Testicular cancer survival by tumour type: number at risk and net survival probabilities, 2015-2024 16
5. CANCER SURVIVAL TRENDS 17
5.1. Testicular cancer survival trends: by tumour stage 17
5.1.1. Testicular cancer survival trends by stage: number at risk and net survival probabilities, 2004-2024 17
5.2. Testicular cancer survival trends: by tumour type 19
5.2.2. Testicular cancer survival trends by tumour type: number at risk and net survival probabilities, 2004-2024 19
6. CANCER MORTALITY 20
6.1. Testicular cancer mortality: by region 20
6.1.1. Testicular cancer mortality* by region: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2023 20
7. CANCER MORTALITY TRENDS 21
7.1. Testicular cancer mortality trends: by region 21
7.1.1. Testicular cancer mortality* trends by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023 21

1.1. Testicular cancer incidence: by region

1.1.1. Testicular cancer incidence by region: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2024

	N [CR]																				ESR2013 (95%CI)
Region	**0-**	**5-**	**10-**	**15-**	**20-**	**25-**	**30-**	**35-**	**40-**	**45-**	**50-**	**55-**	**60-**	**65-**	**70-**	**75-**	**80-**	**85-**	**90-**	**95-**	**All ages**	
Belgium	0	0	0	8	23	71	102	85	70	50	22	17	10	7	4	2	2	1	0	0	474	8.3
	[0.0]	[0.0]	[0.0]	[2.3]	[6.6]	[19.5]	[26.1]	[22.4]	[18.2]	[13.4]	[5.6]	[4.3]	[2.6]	[2.2]	[1.5]	[0.9]	[1.6]	[1.2]	[0.0]	[0.0]	[8.2]	(7.5; 9.0)
Brussels	0	0	0	0	1	6	9	6	4	3	3	3	1	1	0	0	0	0	0	0	37	5.4
	[0.0]	[0.0]	[0.0]	[0.0]	[2.4]	[11.6]	[16.9]	[12.6]	[8.8]	[6.8]	[7.3]	[8.3]	[3.4]	[4.6]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[6.0]	(3.6; 7.2)
Flanders	0	0	0	5	16	46	58	41	39	37	10	11	6	3	2	1	0	1	0	0	276	8.5
	[0.0]	[0.0]	[0.0]	[2.5]	[8.4]	[22.7]	[26.5]	[19.2]	[17.5]	[17.4]	[4.4]	[4.6]	[2.6]	[1.5]	[1.2]	[0.7]	[0.0]	[1.8]	[0.0]	[0.0]	[8.2]	(7.5; 9.5)
Wallonia	0	0	0	3	6	19	35	38	27	10	9	3	3	3	2	1	2	0	0	0	161	9.2
	[0.0]	[0.0]	[0.0]	[2.6]	[5.3]	[17.2]	[29.4]	[32.0]	[23.0]	[8.6]	[7.2]	[2.4]	[2.5]	[2.9]	[2.3]	[1.5]	[5.8]	[0.0]	[0.0]	[0.0]	[8.9]	(7.7; 10.6)

1.2. Testicular cancer incidence: by tumour stage

1.2.2. Testicular cancer incidence by clinical stage (cStage) and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

cStage	N[CR]				ESR2013 (95%CI)
	15-34	35-49	50+	All ages 0+	
I	154 [10.6]	167 [14.7]	44 [2.0]	365 [6.3]	6.4 (5.7; 7.0)
II	24 [1.7]	20 [1.8]	8 [0.4]	52 [0.9]	0.9 (0.7; 1.2)
III	22 [1.5]	14 [1.2]	4 [0.2]	40 [0.7]	0.7 (0.5; 0.9)
X/NA	4 [0.3]	4 [0.4]	9 [0.4]	17 [0.3]	0.3 (0.2; 0.4)

1.2.3. Testicular cancer incidence by pathological stage (pStage) and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

pStage	N[CR]				ESR2013 (95%CI)
	15-34	35-49	50+	All ages 0+	
I	189 [13.0]	189 [16.6]	53 [2.4]	431 [7.4]	7.5 (6.8; 8.2)
II	7 [0.5]	5 [0.4]	0 [0.0]	12 [0.2]	0.2 (0.1; 0.3)
III	3 [0.2]	2 [0.2]	1 [0.0]	6 [0.1]	0.1 (0.0; 0.2)
X/NA	5 [0.3]	9 [0.8]	11 [0.5]	25 [0.4]	0.4 (0.3; 0.6)

1.2.4. Testicular cancer incidence by stage and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

Stage	N[CR]				ESR2013 (95%CI)
	15-34	35-49	50+	All ages 0+	
I	172 [11.8]	183 [16.1]	52 [2.3]	407 [7.0]	7.1 (6.4; 7.8)
II	6 [0.4]	5 [0.4]	0 [0.0]	11 [0.2]	0.2 (0.1; 0.3)
III	22 [1.5]	14 [1.2]	4 [0.2]	40 [0.7]	0.7 (0.5; 0.9)
X/NA	4 [0.3]	3 [0.3]	9 [0.4]	16 [0.3]	0.3 (0.1; 0.4)

1.3. Testicular cancer incidence: by tumour type

1.3.5. Testicular cancer incidence by tumour type and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

Type	N[CR]				ESR2013 (95%CI)
	15-34	35-49	50+	All ages 0+	
Seminoma	101 [6.9]	150 [13.2]	42 [1.9]	293 [5.1]	5.2 (4.6; 5.7)
Non-seminoma	98 [6.7]	49 [4.3]	12 [0.5]	159 [2.7]	2.7 (2.3; 3.2)

Note: Excluding unspecified and rare subtypes.

1.3.6. Testicular cancer incidence by tumour type, stage and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

Sub-type	Stage	Males				
		N[CR]				ESR2013 (95%CI)
		15-34	35-49	50+	All ages 0+	
Seminoma	**I**	96 [6.6]	137 [12.0]	40 [1.8]	273 [4.7]	4.8 (4.2; 5.4)
	II	0 [0.0]	5 [0.4]	0 [0.0]	5 [0.1]	0.1 (0.0; 0.2)
	III	4 [0.3]	7 [0.6]	2 [0.1]	13 [0.2]	0.2 (0.1; 0.4)
	X/NA	1 [0.1]	1 [0.1]	0 [0.0]	2 [0.0]	0.0 (0.0; 0.1)
Non-seminoma	**I**	74 [5.1]	41 [3.6]	10 [0.4]	125 [2.2]	2.2 (1.8; 2.5)
	II	6 [0.4]	0 [0.0]	0 [0.0]	6 [0.1]	0.1 (0.0; 0.2)
	III	17 [1.2]	7 [0.6]	2 [0.1]	26 [0.4]	0.4 (0.3; 0.6)
	X/NA	1 [0.1]	1 [0.1]	0 [0.0]	2 [0.0]	0.0 (0.0; 0.1)

Note: Excluding unspecified and rare subtypes.

2.1. Testicular cancer incidence trends: by region

2.1.1. Testicular cancer incidence trends by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
Belgium	**N**	249	275	274	297	321	309	315	357	355	353	359	377	412	390	403	396	439	438	404	436	474		
	CR	4.9	5.4	5.3	5.7	6.1	5.9	5.9	6.6	6.6	6.5	6.6	6.8	7.4	7.0	7.2	7.0	7.8	7.7	7.1	7.6	8.2		
	ESR2013	4.6	5.1	5.0	5.4	5.8	5.6	5.7	6.4	6.3	6.3	6.4	6.8	7.3	6.9	7.2	7.0	7.8	7.8	7.1	7.6	8.3	2.5 (2.2; 2.8)	2004-2024
																							3.3 (2.7; 3.9)	2004-2015
																							1.6 (0.8; 2.3)	2016-2024
Brussels	**N**	17	21	24	20	30	29	32	26	29	20	32	29	30	30	32	37	37	50	31	39	37		
	CR	3.5	4.3	4.9	4.0	5.9	5.6	6.1	4.8	5.2	3.6	5.6	5.1	5.2	5.2	5.5	6.2	6.2	8.3	5.2	6.4	6.0		
	ESR2013	3.1	4.0	4.3	3.6	4.6	5.0	5.4	3.9	4.9	3.0	4.6	4.4	4.5	4.5	5.0	5.8	5.6	7.5	4.4	5.6	5.4	2.2 (0.9; 3.5)	2004-2024
Flanders	**N**	127	155	149	167	177	179	163	180	212	197	208	213	244	248	215	228	260	243	248	234	276		
	CR	4.3	5.2	5.0	5.5	5.8	5.8	5.3	5.8	6.8	6.3	6.6	6.7	7.6	7.7	6.6	7.0	7.9	7.4	7.5	7.0	8.2		
	ESR2013	4.0	5.0	4.7	5.3	5.6	5.6	5.2	5.7	6.6	6.2	6.6	6.8	7.7	7.8	6.8	7.2	8.2	7.7	7.7	7.3	8.5	2.9 (2.4; 3.4)	2004-2024
																							4.2 (3.3; 5.1)	2004-2016
																							1.1 (-0.3; 2.5)	2017-2024
Wallonia	**N**	105	99	101	110	114	101	120	151	114	136	119	135	138	112	156	131	142	145	125	163	161		

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
	CR	6.4	6.0	6.1	6.6	6.8	6.0	7.1	8.8	6.6	7.8	6.8	7.7	7.9	6.3	8.8	7.4	8.0	8.1	7.0	9.1	8.9		
	ESR2013	6.2	5.7	5.8	6.2	6.5	5.8	6.9	8.6	6.5	7.8	6.7	7.7	7.9	6.4	8.9	7.5	8.0	8.3	7.1	9.2	9.2	1.9 (1.2; 2.7)	2004-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.2. Testicular cancer incidence trends: by tumour stage

2.2.2. Testicular cancer incidence trends by stage: number of new diagnoses, crude and age-standardised incidence rates, 2020-2024, including average annual percentage change from 2004 onwards

Stage		2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
I	**N**	380	369	353	375	407		
	CR	6.7	6.5	6.2	6.5	7.0		
	ESR2013	6.7	6.5	6.2	6.6	7.1	4.1 (3.6; 4.5)	2004-2024
							8.2 (6.3; 10.1)	2004-2010
							3.3 (1.1; 5.6)	2011-2014
							2.0 (1.1; 2.9)	2015-2024
II	**N**	19	20	17	19	11		
	CR	0.3	0.4	0.3	0.3	0.2		
	ESR2013	0.3	0.4	0.3	0.3	0.2	-0.4 (-2.9; 2.3)	2004-2024
III	**N**	26	30	31	31	40		
	CR	0.5	0.5	0.5	0.5	0.7		
	ESR2013	0.5	0.5	0.5	0.5	0.7	3.4 (1.6; 5.1)	2004-2024
X/NA	**N**	14	19	3	11	16		
	CR	0.2	0.3	0.1	0.2	0.3		
	ESR2013	0.3	0.4	0.1	0.2	0.3	-7.7 (-11.3; -3.9)	2004-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.3. Testicular cancer incidence trends: by age group

2.3.3. Testicular cancer incidence trends by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Age		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, %	(95%CI)	Period
15-34	**N**	130	155	148	164	191	174	179	195	191	190	194	199	235	202	178	188	210	216	188	204	204			
	CR	9.7	11.6	11.1	12.3	14.2	12.9	13.2	14.2	13.8	13.7	14.0	14.3	16.9	14.5	12.8	13.4	14.9	15.3	13.2	14.2	14.0			
	ESR2013	9.8	11.7	11.1	12.3	14.4	13.1	13.4	14.4	14.0	13.8	14.0	14.4	17.0	14.5	12.8	13.4	15.0	15.3	13.2	14.2	14.1	1.5	(0.8; 2.2)	2004-2024
																							5.1	(2.4; 7.8)	2004-2010
																							0.7	(-2.5; 3.9)	2011-2014
																							-0.3	(-1.6; 1.1)	2015-2024
35-49	**N**	89	83	95	109	101	108	91	129	123	116	137	136	126	147	179	153	164	161	160	175	205			
	CR	7.5	7.0	7.9	9.1	8.4	9.0	7.6	10.8	10.4	9.9	11.8	11.8	11.0	12.9	15.7	13.5	14.5	14.3	14.2	15.4	18.0			
	ESR2013	7.4	6.9	8.0	9.2	8.5	9.0	7.7	11.0	10.5	10.1	12.1	12.1	11.0	12.9	15.9	13.5	14.5	14.3	14.2	15.4	18.0	4.3	(3.7; 5.0)	2004-2024
50+	**N**	29	37	28	21	28	25	42	30	39	44	27	39	47	40	44	53	63	58	52	55	65			
	CR	1.8	2.2	1.7	1.2	1.6	1.4	2.3	1.6	2.1	2.3	1.4	2.0	2.3	2.0	2.1	2.5	3.0	2.7	2.4	2.5	2.9			
	ESR2013	1.8	2.0	1.5	1.1	1.5	1.3	2.2	1.5	1.9	2.1	1.3	1.9	2.2	1.8	2.0	2.4	2.9	2.7	2.3	2.5	2.9	3.1	(1.6; 4.7)	2004-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

3.1. Testicular cancer prevalence: by region

3.1.1. Testicular cancer prevalence by region: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2024

Region		1-year	5-year	10-year	15-year	20-year
Belgium	**N**	464	2,086	3,877	5,391	6,600
	CR	8.0	35.8	66.5	92	113
	ESR2013	8.1	36.5	68.2	95.1	116.5
Brussels	**N**	35	180	313	425	516
	CR	5.7	29.3	50.9	69.1	83.9
	ESR2013	5.0	26.2	47.4	66.0	81.9
Flanders	**N**	269	1,211	2,273	3,133	3,819
	CR	7.9	35.6	66.9	92.2	112.3
	ESR2013	8.3	37.2	70.1	96.6	117.5
Wallonia	**N**	160	695	1,291	1,833	2,265
	CR	8.8	38.3	71.1	101.0	124.8
	ESR2013	9.1	39.4	73.3	104.4	128.8

4.1. Testicular cancer survival: by region

4.1.1. Testicular cancer survival by region and age group: number at risk and net survival probabilities, 2015-2024

			Net Survival Probability, 2015-2024			
Region	**Age**	**N at risk**	**1-y (95%CI)**	**3-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Belgium	**All ages 15+**	4,059	98.6% (98.2%; 99.0%)	97.7% (97.1%; 98.2%)	97.2% (96.5%; 97.9%)	96.0% (94.7%; 97.3%)
	15-34	1,984	99.4% (99.1%; 99.8%)	98.5% (97.9%; 99.1%)	98.5% (97.8%; 99.1%)	97.6% (96.5%; 98.8%)
	35-49	1,579	99.0% (98.4%; 99.5%)	98.3% (97.5%; 99.0%)	98.0% (97.0%; 98.9%)	98.1% (96.8%; 99.5%)
	50+	510	94.1% (91.9%; 96.4%)	92.4% (89.4%; 95.5%)	90.2% (86.1%; 94.5%)	82.6% (74.5%; 91.5%)
Brussels	**All ages 15+**	341	97.6% (95.9%; 99.3%)	95.1% (92.5%; 97.7%)	95.0% (92.3%; 97.9%)	91.6% (85.1%; 98.6%)
	15-34	166	98.9% (97.2%; 100.5%)	95.8% (92.6%; 99.0%)	95.9% (92.8%; 99.2%)	88.5% (78.0%; 100.4%)
	35-49	130	99.3% (97.8%; 100.8%)	98.9% (96.8%; 101.1%)	99.3% (97.2%; 101.6%)	98.1% (92.5%; 104.0%)
	50+	46	N<50	N<50	N<50	N<50
Flanders	**All ages 15+**	2,340	99.1% (98.7%; 99.6%)	98.8% (98.2%; 99.3%)	98.6% (97.9%; 99.3%)	97.8% (96.3%; 99.2%)
	15-34	1,205	99.6% (99.2%; 100.0%)	99.2% (98.6%; 99.7%)	99.2% (98.6%; 99.8%)	99.1% (98.1%; 100.1%)
	35-49	881	99.3% (98.7%; 99.9%)	98.9% (98.0%; 99.7%)	98.7% (97.6%; 99.7%)	98.3% (96.5%; 100.1%)
	50+	264	96.2% (93.6%; 98.7%)	96.5% (93.1%; 100.0%)	95.8% (91.2%; 100.6%)	89.1% (78.0%; 101.9%)
Wallonia	**All ages 15+**	1,378	97.8% (97.0%; 98.7%)	96.4% (95.2%; 97.6%)	95.4% (93.9%; 96.9%)	93.8% (91.3%; 96.3%)
	15-34	613	99.3% (98.5%; 100.0%)	98.0% (96.8%; 99.2%)	97.7% (96.3%; 99.1%)	96.6% (94.5%; 98.8%)
	35-49	568	98.3% (97.1%; 99.4%)	97.2% (95.7%; 98.8%)	96.5% (94.7%; 98.4%)	97.7% (95.6%; 99.9%)
	50+	200	92.3% (88.4%; 96.5%)	89.4% (84.1%; 94.9%)	85.4% (78.1%; 93.3%)	74.2% (62.3%; 88.5%)

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

4.2. Testicular cancer survival: by tumour stage

4.2.2. Testicular cancer survival by clinical stage (cStage): number at risk and net survival probabilities, 2015-2024

		Net Survival Probability, 2015-2024					
cStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	4,059	98.6% (98.2%; 99.0%)	98.1% (97.6%; 98.6%)	97.7% (97.1%; 98.2%)	97.6% (96.9%; 98.2%)	97.2% (96.5%; 97.9%)	96.0% (94.7%; 97.3%)
I	3,153	99.7% (99.4%; 99.9%)	99.6% (99.3%; 100.0%)	99.4% (98.9%; 99.8%)	99.5% (99.0%; 100.0%)	99.4% (98.8%; 99.9%)	98.6% (97.5%; 99.8%)
II	508	99.2% (98.3%; 100.0%)	98.3% (97.1%; 99.6%)	98.3% (97.0%; 99.6%)	97.7% (96.1%; 99.3%)	97.3% (95.5%; 99.1%)	95.3% (91.5%; 99.2%)
III	286	89.3% (85.8%; 93.0%)	86.6% (82.7%; 90.7%)	85.1% (81.0%; 89.5%)	84.3% (80.0%; 88.9%)	83.9% (79.4%; 88.6%)	83.6% (78.9%; 88.6%)
X/NA	128	88.8% (83.2%; 94.8%)	85.6% (79.1%; 92.7%)	81.0% (73.3%; 89.6%)	79.1% (70.6%; 88.5%)	75.3% (66.0%; 86.0%)	63.4% (49.6%; 81.1%)

4.2.3. Testicular cancer survival by pathological stage (pStage): number at risk and net survival probabilities, 2015-2024

		Net Survival Probability, 2015-2024					
pStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	4,059	98.6% (98.2%; 99.0%)	98.1% (97.6%; 98.6%)	97.7% (97.1%; 98.2%)	97.6% (96.9%; 98.2%)	97.2% (96.5%; 97.9%)	96.0% (94.7%; 97.3%)
I	3,635	99.4% (99.2%; 99.7%)	99.4% (99.0%; 99.7%)	99.2% (98.8%; 99.6%)	99.2% (98.7%; 99.6%)	99.0% (98.4%; 99.6%)	98.1% (97.0%; 99.3%)
II	153	97.5% (95.0%; 100.1%)	96.3% (93.3%; 99.5%)	95.0% (91.5%; 98.8%)	95.2% (91.6%; 98.9%)	95.3% (91.7%; 99.1%)	96.2% (92.6%; 100.0%)
III	85	93.1% (87.9%; 98.7%)	83.9% (76.3%; 92.1%)	80.3% (72.1%; 89.4%)	80.4% (72.2%; 89.6%)	80.6% (72.4%; 89.8%)	81.8% (73.5%; 91.1%)
X/NA	194	85.6% (80.6%; 90.9%)	82.4% (76.9%; 88.4%)	78.9% (72.7%; 85.7%)	77.5% (70.7%; 84.8%)	74.1% (66.8%; 82.2%)	64.0% (53.1%; 77.2%)

4.2.4. Testicular cancer survival by stage: number at risk and net survival probabilities, 2015-2024

		Net Survival Probability, 2015-2024					
Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	4,059	98.6% (98.2%; 99.0%)	98.1% (97.6%; 98.6%)	97.7% (97.1%; 98.2%)	97.6% (96.9%; 98.2%)	97.2% (96.5%; 97.9%)	96.0% (94.7%; 97.3%)
I	3,471	99.7% (99.5%; 99.9%)	99.7% (99.4%; 100.0%)	99.5% (99.1%; 99.9%)	99.5% (99.0%; 99.9%)	99.3% (98.8%; 99.9%)	98.4% (97.2%; 99.6%)
II	160	98.3% (96.2%; 100.4%)	96.5% (93.6%; 99.6%)	95.4% (91.9%; 99.0%)	95.6% (92.1%; 99.2%)	94.9% (91.1%; 98.9%)	94.8% (90.2%; 99.6%)
III	311	89.8% (86.5%; 93.3%)	86.7% (83.0%; 90.6%)	85.4% (81.5%; 89.6%)	84.7% (80.6%; 89.0%)	84.3% (80.1%; 88.7%)	84.2% (79.8%; 88.9%)
X/NA	126	88.6% (82.9%; 94.7%)	85.4% (78.8%; 92.5%)	80.8% (73.0%; 89.4%)	78.8% (70.3%; 88.4%)	75.0% (65.5%; 85.8%)	63.1% (49.3%; 80.8%)

4.3. Testicular cancer survival: by tumour type

4.3.5. Testicular cancer survival by tumour type: number at risk and net survival probabilities, 2015-2024

		Net Survival Probability, 2015-2024					
type	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	4,059	98.6% (98.2%; 99.0%)	98.1% (97.6%; 98.6%)	97.7% (97.1%; 98.2%)	97.6% (96.9%; 98.2%)	97.2% (96.5%; 97.9%)	96.0% (94.7%; 97.3%)
Seminoma	2,301	99.4% (99.0%; 99.8%)	99.5% (99.1%; 99.9%)	99.1% (98.5%; 99.7%)	99.1% (98.4%; 99.7%)	98.8% (98.0%; 99.6%)	97.6% (96.0%; 99.3%)
Non-seminoma	1,577	97.8% (97.1%; 98.6%)	96.9% (96.0%; 97.8%)	96.7% (95.8%; 97.6%)	96.6% (95.6%; 97.6%)	96.4% (95.3%; 97.4%)	95.8% (94.2%; 97.4%)

Note: Excluding unspecified and rare subtypes.

5.1. Testicular cancer survival trends: by tumour stage

5.1.1. Testicular cancer survival trends by stage: number at risk and net survival probabilities, 2004-2024

Period	Stage	Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
2004-2009	**Total**	1,677	98.4% (97.8%; 99.1%)	97.0% (96.1%; 97.9%)	96.4% (95.3%; 97.5%)
	I	1,246	99.4% (98.8%; 99.9%)	98.7% (97.9%; 99.5%)	98.4% (97.3%; 99.4%)
	II	105	100.0% (100.0%; 100.0%)	97.7% (94.6%; 100.9%)	96.9% (93.2%; 100.6%)
	III	119	90.0% (84.7%; 95.6%)	80.9% (74.0%; 88.4%)	77.7% (70.4%; 85.8%)
	X/NA	212	96.2% (93.5%; 98.9%)	94.7% (91.2%; 98.2%)	93.3% (89.4%; 97.4%)
2010-2014	**Total**	1,700	98.6% (98.0%; 99.2%)	97.6% (96.7%; 98.4%)	97.3% (96.3%; 98.3%)
	I	1,415	99.8% (99.4%; 100.1%)	99.1% (98.4%; 99.8%)	98.9% (98.0%; 99.8%)
	II	68	95.8% (91.0%; 100.8%)	94.4% (89.0%; 100.2%)	95.1% (89.6%; 100.9%)
	III	131	92.5% (88.1%; 97.2%)	88.2% (82.7%; 94.0%)	87.1% (81.3%; 93.2%)
	X/NA	87	91.4% (85.5%; 97.7%)	88.3% (81.4%; 95.7%)	88.0% (80.4%; 96.3%)
2015-2019	**Total**	1,929	98.9% (98.4%; 99.4%)	98.0% (97.3%; 98.8%)	97.7% (96.8%; 98.6%)
	I	1,634	99.9% (99.6%; 100.1%)	99.8% (99.3%; 100.2%)	99.7% (99.0%; 100.4%)
	II	74	97.5% (93.8%; 101.2%)	93.7% (88.2%; 99.6%)	93.7% (88.2%; 99.6%)
	III	156	91.8% (87.6%; 96.3%)	86.4% (81.1%; 92.0%)	85.4% (79.9%; 91.3%)
	X/NA	67	92.0% (85.3%; 99.1%)	86.6% (77.7%; 96.6%)	81.3% (70.2%; 94.1%)

Period	Stage	Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
2020-2024	**Total**	2,151	98.3% (97.7%; 98.9%)	97.3% (96.5%; 98.1%)	96.8% (95.7%; 97.9%)
	I	1,854	99.5% (99.2%; 99.9%)	99.2% (98.6%; 99.8%)	99.1% (98.2%; 99.9%)
	II	86	99.0% (96.8%; 101.3%)	96.8% (92.7%; 101.2%)	94.8% (88.9%; 101.2%)
	III	155	87.8% (82.8%; 93.2%)	84.3% (78.6%; 90.5%)	83.2% (77.1%; 89.9%)
	X/NA	59	84.6% (75.5%; 94.9%)	72.6% (60.0%; 87.8%)	66.7% (51.4%; 86.5%)

5.2. Testicular cancer survival trends: by tumour type

5.2.2. Testicular cancer survival trends by tumour type: number at risk and net survival probabilities, 2004-2024

Period	type	Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
2004-2009	**Total**	1,677	98.4% (97.8%; 99.1%)	97.0% (96.1%; 97.9%)	96.4% (95.3%; 97.5%)
	Seminoma	876	98.8% (98.0%; 99.6%)	98.0% (96.9%; 99.2%)	98.4% (97.1%; 99.8%)
	Non-seminoma	726	98.6% (97.8%; 99.5%)	96.5% (95.0%; 97.9%)	94.8% (93.0%; 96.6%)
2010-2014	**Total**	1,700	98.6% (98.0%; 99.2%)	97.6% (96.7%; 98.4%)	97.3% (96.3%; 98.3%)
	Seminoma	944	99.3% (98.6%; 99.9%)	98.7% (97.7%; 99.7%)	98.4% (97.2%; 99.7%)
	Non-seminoma	699	98.0% (96.9%; 99.1%)	96.2% (94.8%; 97.8%)	95.9% (94.4%; 97.6%)
2015-2019	**Total**	1,929	98.9% (98.4%; 99.4%)	98.0% (97.3%; 98.8%)	97.7% (96.8%; 98.6%)
	Seminoma	1,059	99.7% (99.2%; 100.2%)	99.5% (98.7%; 100.2%)	99.4% (98.4%; 100.4%)
	Non-seminoma	783	98.2% (97.2%; 99.2%)	96.9% (95.6%; 98.2%)	96.6% (95.2%; 98.0%)
2020-2024	**Total**	2,151	98.3% (97.7%; 98.9%)	97.3% (96.5%; 98.1%)	96.8% (95.7%; 97.9%)
	Seminoma	1,253	99.1% (98.5%; 99.7%)	98.7% (97.8%; 99.6%)	98.2% (96.9%; 99.5%)
	Non-seminoma	801	97.5% (96.4%; 98.6%)	96.5% (95.2%; 97.9%)	96.4% (94.9%; 97.9%)

Note: Excluding unspecified and rare subtypes.

6.1. Testicular cancer mortality: by region

6.1.1. Testicular cancer mortality by region: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2023*

Region	N [CR] 0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	ESR2013 (95%CI)
Belgium	0	0	0	0	0	3	1	4	0	0	1	0	4	0	0	0	1	0	0	0	14	0.2
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.8]	[0.3]	[1.1]	[0.0]	[0.0]	[0.3]	[0.0]	[1.1]	[0.0]	[0.0]	[0.0]	[0.8]	[0.0]	[0.0]	[0.0]	[0.2]	(0.1; 0.4)
Brussels	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	2	0.3
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.4]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	(0.0; 0.7)
Flanders	0	0	0	0	0	1	1	1	0	0	0	0	1	0	0	0	1	0	0	0	5	0.1
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[0.5]	[0.5]	[0.0]	[0.0]	[0.0]	[0.0]	[0.4]	[0.0]	[0.0]	[0.0]	[1.2]	[0.0]	[0.0]	[0.0]	[0.1]	(0.0; 0.3)
Wallonia	0	0	0	0	0	1	0	3	0	0	0	0	3	0	0	0	0	0	0	0	7	0.4
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[0.0]	[2.6]	[0.0]	[0.0]	[0.0]	[0.0]	[2.6]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.4]	(0.1; 0.7)

7.1. Testicular cancer mortality trends: by region

7.1.1. Testicular cancer mortality trends by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023*

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Belgium	**N**	8	12	11	9	16	5	10	9	14	10	11	11	10	11	11	16	17	16	13	14		
	CR	0.2	0.2	0.2	0.2	0.3	0.1	0.2	0.2	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.3	0.3	0.3	0.2	0.2		
	ESR2013	0.3	0.3	0.3	0.2	0.3	0.2	0.2	0.2	0.3	0.2	0.3	0.2	0.2	0.2	0.2	0.3	0.3	0.3	0.2	0.2	0.6 (-1.2; 2.3)	2004-2023
Brussels	**N**	1	0	0	0	2	0	3	2	1	0	1	2	1	2	5	1	2	0	0	2		
	CR	0.2	0.0	0.0	0.0	0.4	0.0	0.6	0.4	0.2	0.0	0.2	0.3	0.2	0.3	0.9	0.2	0.3	0.0	0.0	0.3		
	ESR2013	0.5	0.0	0.0	0.0	0.3	0.0	0.5	0.7	0.3	0.0	0.1	0.5	0.1	0.3	0.9	0.1	0.5	0.0	0.0	0.3	NA	2004-2023
Flanders	**N**	3	5	5	7	9	4	5	2	5	7	3	7	4	3	3	6	8	11	11	5		
	CR	0.1	0.2	0.2	0.2	0.3	0.1	0.2	0.1	0.2	0.2	0.1	0.2	0.1	0.1	0.1	0.2	0.2	0.3	0.3	0.1		
	ESR2013	0.2	0.2	0.2	0.2	0.3	0.2	0.2	0.1	0.2	0.2	0.1	0.2	0.1	0.1	0.1	0.2	0.3	0.3	0.3	0.1	0.2 (-3.3; 3.9)	2004-2023
																						-6.3 (-11.8; -0.5)	2004-2016
																						12.6 (0.8; 25.8)	2017-2023
Wallonia	**N**	4	7	6	2	5	1	2	5	8	3	7	2	5	6	3	9	7	5	2	7		
	CR	0.2	0.4	0.4	0.1	0.3	0.1	0.1	0.3	0.5	0.2	0.4	0.1	0.3	0.3	0.2	0.5	0.4	0.3	0.1	0.4		
	ESR2013	0.2	0.4	0.4	0.1	0.3	0.1	0.2	0.3	0.5	0.2	0.7	0.1	0.3	0.4	0.2	0.5	0.4	0.3	0.1	0.4	1.8 (-3.3; 7.2)	2004-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

*Mortality statistics in Belgium are collected and managed by the three Regions (Flemish Region: Departement Zorg; Brussels-Capital Region: Observatorium voor Gezondheid en Welzijn van Brussel-Hoofdstad/ l'Observatoire de la Santé et du Social de Bruxelles-Capitale; Walloon Region: Agence Wallonne de la Santé, de la Protection sociale, du Handicap et des Familles (AVIQ)). The Directorate General Statistics Belgium is responsible for collecting and merging the data coming from the regional agencies. Mortality data used in this cancer fact sheet are collected from the Directorate General Statistics Belgium and encompasses the period 2004-2023.

Recommended reference: Cancer Fact Sheets 2024, Belgian Cancer Registry (BCR), 2026